Requiring conventional sample size calculations might be an impediment to completing translational or early clinical studies, write Peter Bacchetti and his colleagues at the University of California, San Francisco, in a Perspectives article in Science Translational Medicine. "There is little theoretical or empirical support for the conventional requirement that every study must have at least 80% power," the authors write.